Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chain (AL)-Amyloidosis
Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
This is a phase 1/2 open-label, dose-escalation study investigating single-agent therapy with
VELCADE in patients with previously treated systemic AL-amyloidosis who require further
treatment.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Millennium Pharmaceuticals, Inc.
Collaborator:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.